Cargando…

Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products

Objective: Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig(®) treatment offered a tolerable and safe alternative treatment for immunodeficient patients. Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brownlee, Sydney, Allen, Crystal, Kana’an, Mohammed F., Cameron, D. William, Cowan, Juthaporn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680362/ https://www.ncbi.nlm.nih.gov/pubmed/36412628 http://dx.doi.org/10.3390/hematolrep14040048

Ejemplares similares

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H, et al.
Publicado: (2022)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2019)

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
por: Gupta, Sudhir, et al.
Publicado: (2023)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2022)

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
por: Keith, Paul K., et al.
Publicado: (2022)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
por: Keith, Paul K., et al.
Publicado: (2023)

Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
por: Rosenbach, Kevin, et al.
Publicado: (2023)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study
por: Anderson, John T., et al.
Publicado: (2021)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study
por: Cowan, Juthaporn, et al.
Publicado: (2020)

Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency
por: Walter, Jolan E., et al.
Publicado: (2010)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021)

Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry
por: Abadeh, Armin, et al.
Publicado: (2023)

Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations
por: Unninayar, Dana, et al.
Publicado: (2021)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab
por: Zhu, Changhua, et al.
Publicado: (2022)

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency
por: Dinh, Tri, et al.
Publicado: (2019)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Levels of immunoglobulin isotypes in serum and respiratory samples of patients with chronic obstructive pulmonary disease: protocol for a systematic review and meta-analysis
por: Unninayar, Dana, et al.
Publicado: (2023)

Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation
por: Cowan, Juthaporn, et al.
Publicado: (2015)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy
por: Roger, Albert, et al.
Publicado: (2014)

Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion
por: Rosebraugh, Matthew, et al.
Publicado: (2021)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
por: Isa, Flonza, et al.
Publicado: (2022)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
por: Corren, Jonathan, et al.
Publicado: (2021)

Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study
por: Bourque, P. R., et al.
Publicado: (2016)

Who Did It?
por: Bainbridge, Laura
Publicado: (1887)

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
por: Fasshauer, Maria, et al.
Publicado: (2023)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

Clinical outcomes of immunoglobulin use in solid organ transplant recipients: protocol for a systematic review and meta-analysis
por: Cowan, Juthaporn, et al.
Publicado: (2015)

In vivo screening of subcutaneous tolerability for the development of novel excipients
por: Takai, Yuichi, et al.
Publicado: (2022)

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
por: Kanegane, Hirokazu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l0vvk2rj4pukfre8pgoaea4i8f